What Is Mazdutide?
Mazdutide (IBI362/OXM3) is a once-weekly injectable dual agonist of GLP-1 and glucagon receptors developed by Innovent Biologics. Unlike pure GLP-1 agonists, Mazdutide's glucagon receptor component adds energy expenditure enhancement and hepatic fat reduction, positioning it as both an obesity and NASH (non-alcoholic steatohepatitis) treatment candidate.
Dual Mechanism Advantage
GLP-1 receptor agonism provides appetite suppression, glucose-dependent insulin secretion, and slowed gastric emptying. Glucagon receptor agonism adds increased energy expenditure through thermogenesis and lipolysis, and — most distinctively — direct reduction of hepatic fat through glucagon's ability to drive liver fat oxidation. The combination produces weight loss that includes preferential liver fat reduction, addressing the hepatic component of metabolic syndrome that pure GLP-1 agonists address less directly.
Clinical Data
Phase 2 trials reported mean weight losses of approximately 10–11% body weight over 24 weeks in adults with obesity or overweight. In subjects with T2D, significant HbA1c reductions were observed alongside weight loss. Phase 3 trials in obesity and NASH are ongoing.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
Ji L, Jiang H, Bi Y, Li H, Tian J, Liu D, Zhao Y, Qiu W, Huang C, Chen L, et al., 2025, N Engl J Med - Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity
Ji L, Gao L, Jiang H, Yang J, Yu L, Wen J, Cai C, Deng H, Feng L, Song B, Ma Q, Qian L, 2022, eClinicalMedicine - Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Zhang B, Cheng Z, Chen J, Wu T, Yang Y, Wang B, Guan M, Zhao M, Mu Y, 2024, Diabetes Care - Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials
Nalisa DL, Cuboia N, Dyab E, et al., 2024, Front Endocrinol (Lausanne) - Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial
Bhattachar SN, et al., 2025, Diabetes Obes Metab - A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity
He Q, Shang W, Zhou J, et al., 2023, Nat Commun - Emerging pharmacotherapies for obesity: A systematic review
Kokkorakis M, Chakhtoura M, Rhayem C, 2025, Pharmacol Rev - Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son JW, le Roux CW, Blüher M, 2026, Endocr Rev - Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials
Xie Z, Zheng G, Liang Z, 2024, Metabolism - Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Zhang B, Cheng Z, Chen J, 2024, Diabetes Care - Mazdutide versus placebo in Chinese adults with type 2 diabetes
Zhu D, Zhao J, Cai H, 2026, Nature